Malignant Tumor Treatment Technologies, Inc. (Headquarters: Tokyo; President and CEO: Toshiyasu Miyazaki; “M.T.3”) announced today that the Japanese pharmaceutical regulatory agency, the Ministry of Agriculture, Forestry, and Fisheries, has granted approval for LAVURCHIN® as a radiation sensitizing agent for dogs with stage III or stage IV nasal cavity tumors.
Radiation therapy, a crucial treatment for malignant tumors that cannot be completely removed through surgery, has seen significant advancements in recent years in both human and veterinary medicine. However, challenges such as limitations on the number of radiation sessions and decreased effectiveness as tumors progress have highlighted the need for a radiation sensitizing agent to enhance treatment outcomes. Despite several candidate substances being studied, none have obtained pharmaceutical approval due to concerns about side effects.
After a long and challenging endeavor lasting over two and a half decades, "LAVURCHIN®" has emerged as a groundbreaking solution as the world’s first radiation sensitizing agent in the veterinary field approved by the Japanese Ministry of Agriculture, Forestry, and Fisheries (MAFF), the U.S. Food and Drug Administration (FDA), and the European Medicines Agency (EMA). Derived from marine organisms, including sea urchins from Hokkaido, a northern region of Japan, and deep-sea seaweed, this innovative agent not only enhances the effects of radiation therapy but also minimizes damage to normal tissues, ensuring high safety standards.
"We are delighted to announce the approval of LAVURCHIN® as the world's first radiation sensitizing agent for dogs," said Toshiyasu Miyazaki, President and CEO of M.T.3. "This significant milestone is a testament to our commitment to advancing cancer treatment and improving the lives of both animals and humans. We will continue our endeavors to make LAVURCHIN® available to those in need around the world."
In parallel with the Japanese approval, M.T.3 is conducting clinical research on "LAVURCHIN®" in the United States, demonstrating a global perspective. The company envisions bringing this revolutionary product to markets worldwide, including the United States, Europe, and Asia. Furthermore, future expansion into human medicine is also being considered.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DE-INCYTE29.9.2023 19:44:31 CEST | Press release
Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress
CA-ANDERSEN-GLOBAL29.9.2023 17:25:34 CEST | Pressemeddelelse
Andersen lancerer global værdiansættelsespraksis
Q429.9.2023 17:13:42 CEST | Press release
Q4 Inc. Recognized as one of Canada’s Top Growing Companies by The Globe and Mail
CA-GEDI-CUBE29.9.2023 15:49:11 CEST | Press release
GEDi Cube and Renovaro Biosciences Sign Definitive Agreement to Combine
ALLIANZ-SE29.9.2023 13:54:35 CEST | Press release
Offshore Windfarm Hollandse Kust Zuid Inaugurated
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom